John Ratliff is CEO of Covance Drug Development, the world’s most comprehensive drug development company and the only provider of full-spectrum drug development services from early-stage research to regulatory approval and beyond. Covance provides a wide range of drug research, development and market-access solutions to pharmaceutical, biotechnology and medical device companies across the world.
Ratliff is a highly respected biopharmaceutical leader, with extensive experience in increasingly important roles in the industry. Most recently, he served as president and CEO of HUYA Bioscience International, a leader in globalizing biopharma innovation. Ratliff’s experience in biopharma also includes nearly 10 years at Quintiles, one of the world’s largest providers of product development and integrated healthcare services, joining as chief financial officer in 2004, becoming chief operating officer in 2006, and president and COO in 2010. He led Quintiles’ global services organization, with its clinical research, commercial, consulting, and lab operations, and was a member of the company’s board of directors.
Prior to joining Covance, Ratliff was involved with Remarque Systems, a provider of risk-based monitoring (RBM) software solutions, and other entrepreneurial endeavors. Ratliff also joined the advisory board at T3D Therapeutics, Inc., a clinical stage drug development company engaged in the development of a new orally administered treatment for Alzheimer’s disease (AD).
Previous roles throughout his career also include serving as chief financial officer at Acterna, a provider of communications test solutions for telecommunications and cable network operators; and in positions of increasing responsibility during his 19-year tenure at IBM.
Ratliff holds a bachelor’s degree in industrial and systems engineering, summa cum laude, from the Georgia Institute of Technology in Atlanta and a master’s degree in business administration from Duke University in Durham, North Carolina.
Covance is one of two primary business segments of Laboratory Corporation of America® Holdings (LabCorp; NYSE: LH). LabCorp, an S&P 500 company, is the world’s leading healthcare diagnostics company, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster and develops technology-enabled solutions to change the way care is provided. With net revenue in excess of $8.5 billion in 2015, LabCorp’s 50,000 employees serve clients in 60 countries.